Teva introduces generic Intuniv
JERUSALEM — The latest addition to Teva’s roster of medication is its generic version of Intuniv (guanfacine) extended release tablets in 1-, 2-, 3- and 4-mg dosage strengths.
Intuniv, which according to March IMS data made $804 million in total sales, is meant to treat attention deficit hyperactivity disorder. The launch of guanfacine brings Teva’s total number of ADHD drugs to eight, and it is the first non-stimulant ADHD drug in its portfolio.
“We recognize the need to make affordable generic treatment options available to patients with ADHD,” Brendan O’Grady, Teva’s President and CEO, North America Generic Medicines, said.
Drug Channels reports pharmacist salaries up 1.6%
PHILADELPHIA – It pays to be a retail pharmacist. Retail pharmacist salaries were up 1.6% on average to $119,400 in 2014, according to the Drug Channels’ exclusive annual analysis of pharmacist salaries, based on the Bureau of Labor Statistics’ recently released Occupational Employment Statistics.
"For the third consecutive year, pharmacists at mass merchants had the highest average salaries, earning a full-time average of $123,000," noted Adam Fein, CEO Drug Channels Institute, in a blog deliniating pharmacist salaries. "Annual salaries at supermarkets and mail pharmacies were lower."
According to the Drug Channels analysis, retail, mail and specialty pharmacies accounted for 63% of total U.S. pharmacist employment, which comprised about 291,000 people.
Teva intros generic Actonel
JERUSALEM — Teva announced Monday that it had launched its generic version of Actonel (risedronate sodium) in 5-, 30- and 35-mg dosage strengths. Teva’s generic will have 180 days of market exclusivity because the company was the first to file for approval from the Food and Drug Administration.
Actonel is meant for the treatment or prevention of osteoporosis in post-menopausal women, increase bone mass or treat osteoporosis in men or women on a corticosteroid. It can also be used to treat Paget’s disease of the bone.
Loading Post Please Wait...